Why is DBV Technologies stock sliding today?

DBV Technologies stock fell -10.0% to trade at €1.72 after the company’s third-quarter 2026 results, released the prior evening, contained a formal going-concern warning stating that management concluded its existing cash is not expected to be sufficient to fund operations for at least twelve months from the date the financial statements were issued.

DBV’s management concluded that its cash position was not expected to cover at least twelve months of operations, with the $165.7 million on hand estimated to fund the company only into the third quarter of 2027.

The company acknowledged it would need to raise additional capital and was evaluating options including further ATM program sales, equity transactions, and warrant exercises, with no guarantee that any of these avenues would be available on acceptable terms.

Compounding investor concern, the Q3 filing also pushed the toddler BLA to 2027 and provided the first concrete timeline for resolving issues at the Fareva Amboise manufacturing facility.

The company posted a Q3 net loss of $64.5 million, nearly double the $33.2 million recorded a year earlier, as R&D costs climbed to $47 million from $28.6 million — partly reflecting BLA filing fees and inventory build — while sales and marketing expenses surged to $5.3 million from $1.2 million and administrative costs rose to $14 million from $7.3 million as DBV scaled its commercial organization.

The FDA’s warning letter issued in April 2026 to Fareva Amboise, DBV’s contract manufacturer, remained an additional overhang on the stock.

French markets faced a particularly heavy session on October 29, with investors adopting a cautious stance following mixed results from major U.S. technology companies. DBV was among the weakest performers on the Paris exchange, with the going-concern disclosure amplifying selling pressure that was already present across risk-sensitive, pre-revenue biotech names.

The combination of a formal solvency warning, a near-doubling of quarterly losses, a delayed toddler BLA, and an unresolved manufacturing issue at its key contract facility proved too much for investors to absorb in a single session — sending the stock to €1.72, well below its open of €1.74 and approaching its 52-week low of €1.53, even as the company’s VIASKIN® Peanut Patch BLA for children aged 4–7 remains under FDA review.